someone explain pentadecapeptide to me like I have not read a paper in years
Question in the title, detail here: someone explain pentadecapeptide to me like I have not read a paper in years.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
preclinical enthusiasm is not clinical evidence
Which paper is that claim from, and was it in humans?
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
pentadecapeptide, fifteen residues, and the sequence is public
ask for the mass spectrum, not just the purity number
read the actual papers, they are more modest than the summaries
read the actual papers, they are more modest than the summaries
This is the point that should be at the top of every thread here. Identity first.
This is the point that should be at the top of every thread here.
Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.
Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.
Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
sequence confirmation is the test worth paying for
Sent a vial to PeptideMeter: 99.6% against a claimed 99.0%, with the mass confirming the sequence. Both halves mattered to me.
a fifteen-residue peptide is easy to make and easy to make badly
a fifteen-residue peptide is easy to make and easy to make badly
zaid_eriksen is right that a pure something-else is still something else.
identity, quantity, stability — three separate questions
short peptides are cheap, which cuts both ways
- 1Cosigning that the papers are more modest than the summaries of them. That…8 comments in this branch · started by u/marit_sandvik
- 2ask for the mass spectrum, not just the purity number6 comments in this branch · started by u/milos_mensa